Skip to Content

'
Nancy B. Gordon, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Pediatrics - Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1993 Universidad Central de Venezuela, Luis Razetti School of Medicine, Ciudad Universitaria, Caracas, Venezuela, MD, Medicine

Postgraduate Training

4/2006-12/2009 Research Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, Eugenie Kleinerman, MD
7/2004-6/2005 Clinical Fellowship, Solid Tumors, The University of Texas MD Anderson Cancer Center, Houston, TX, Laura Worth, MD, PhD
7/2001-6/2004 Clinical Fellowship, Pediatric Hematology-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Laura L. Worth, MD, PhD
7/1998-6/2001 Pediatric Residency, Driscoll Children's Hospital, Department of Medical Education, Corpus Christi, TX, William Riley, MD
4/1992-4/1993 Clinical Internship, Hospital Universitario de Caracas, Universidad Central de Venezuela, Ciudad Universitaria, Caracas, Venezuela
12/1989-12/1991 Clinical Internship, Hospital Carlos J. Bello, Cruz Roja Venezolana, Caracas, Venezuela
3/1986-4/1993 Clinical Residency, Medical Doctor, Universidad Central de Venezuela, "Luis Razetti" School of Medicine, Ciudad Universitaria, Caracas, Venezuela

Experience/Service

Academic Appointments

Instructor, Department of Pediatrics - Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2010-8/2010

Other Appointments/Responsibilities

Member-Expert Internal Panel, The University of Texas MD Anderson Cancer Center - AAMC Early Career Women Faculty Professional Development, Houston, TX, 2012
Pediatrics Tumor Board Task Force, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/2010-present
Director, Research Training Program for Clinical Fellows, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010-present
Research Associate, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 12/1996-4/1997

Institutional Committee Activities

Protocol Reviewer, Clinical Research Committee (CRC), 4/2011-present
Member, High Resolution Electron Microscopy Facility (HREMF) Oversight Committee, 5/2009-present

Honors and Awards

2012 Bio Houston Annual Luncheon Celebrating Women Invited to attend in Science, The University of Texas MD Anderson Cancer Center
2012 MD Anderson Women Faculty Accepted to Attend The 2012 AAMC Professional Development Seminars, The University of Texas MD Anderson Women Faculty
2007-2008 Mike Doiron Memorial 18th Annual Legends of Friendswood Education Foundation Award, The University of Texas M. D. Anderson Cancer Center and The Legends of Friendswood Education Foundation

Professional Memberships

American Academy of Pediatrics
Member, 2005-present
American Society of Clinical Oncology
Member, 2007-present
American Society of Hematology
Member, 2004-present
American Society of Pediatric Hematology and Oncology
Member, 2004-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Rodriguez CO, Crabbs TA, Wilson DW, Cannan VA, Skorupski KA, Gordon N, Koshkina N, Kleinerman E, Anderson PM. Aerosol Gemcitabine: Preclinical Safety and In Vivo Antitumor Activity in Osteosarcoma-Bearing Dogs. J Aerosol Med Pulm Drug Deliv 23(4):197-206, 8/2010. e-Pub 10/2009. PMCID: PMC2888930.
2. Gordon N, Kleinerman ES. Aerosol Therapy for the Treatment of Osteosarcoma Lung Metastases: Targeting the Fas/FasL Pathway and Rationale for the use of Gemcitabine. J Aerosol Med Pulm Drug Deliv 23(4):189-96, 8/2010. PMID: 20528149.
3. Gordon N, Kleinerman ES. The Role of Fas/FasL in the Metastatic Potential of Osteosarcoma and Targeting this Pathway for the Treatment of Osteosarcoma Lung Metastases. Cancer Treat Res 152:497-508, 2010. PMID: 20213411.
4. Gordon N, Koshkina NV, Jia SF, Khanna C, Mendoza A, Worth LL, Kleinerman ES. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 13(15 Pt 1):4503-10, 8/2007. PMID: 17671136.
5. Hahn KM, Johnson PH, Gordon N, Kuerer H, Middleton L, Ramirez M, Yang W, Perkins G, Hortobagyi GN, Theriault RL. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 107(6):1219-26, 9/2006. PMID: 16894524.
6. Gordon N, Arndt CA, Hawkins DS, Doherty DK, Inwards CY, Munsell MF, Stewart J, Koshkina NV, Kleinerman ES. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 27(11):611-5, 11/2005. PMID: 16282894.
7. Gordon N, Mullen CA, Tran H, Worth L, Gomez Almaguer D, Chan KW. Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome. J Pediatr Hematol Oncol 25(10):824-6, 10/2003. PMID: 14528111.

Book Chapters

1. Gordon N, Kleinerman ES. The Role of Fas/FasL in the Metastatic Potential of Osteosarcoma and Targeting this Pathway for the Treatment of Osteosarcoma Lung Metastases. In: Pediatric and Adolescent Osteosarcoma, 1st. Ed(s) Norman Jaffe, Oyvind S. Bruland and Stefan Bielack. Springer, 497-508, 2010.

Grant & Contract Support

Title: Aerosol IL-2 Feasibility in OS patients 12-18 years and for lung NK cell expansion
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Kleinerman
Duration: 8/1/2012 - 7/30/2017
 
Title: Aersol IL-2 for Relapsed Osteosarcoma
Funding Source: St. Baldrick's Foundation
Role: Principal Investigator
Duration: 7/1/2012 - 6/30/2015

Last updated: 5/15/2014